High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globally Combined in-licensing and financing for a novel long-acting clinical ...
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
22h
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
GlobalData on MSN1d
AerWave Medical concludes study of ultrasound therapy for COPDThe study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.
The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectivelyMore than 3,500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback